Back to top
more

ICU Medical (ICUI)

(Delayed Data from NSDQ)

$178.55 USD

178.55
194,349

-0.46 (-0.26%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $178.62 +0.07 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Shrabana Mukherjee headshot

2 Stocks in Focus as New Analysts Initiate Coverage

by Shrabana Mukherjee

The recent surge in analyst coverage for stocks such as ICU Medical (ICUI) and Ardmore Shipping (ASC) indicates the potential for significant price appreciation in the near term.

Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BellRing Brands (BRBR) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

BellRing Brands (BRBR) delivered earnings and revenue surprises of 10.26% and 5.51%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Owens & Minor (OMI) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Owens & Minor (OMI) delivered earnings and revenue surprises of 22.22% and 1.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Do Options Traders Know Something About ICU Medical (ICUI) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to ICU Medical (ICUI) stock based on the movements in the options market lately.

ICU Medical's (ICUI) Plum Duo With Safety Shield Gets 510(k) Nod

by Zacks Equity Research

The Plum Duo infusion pump represents the latest addition to ICU Medical's (ICUI) advanced lineup of infusion devices.

ICU Medical (ICUI) Beats Q2 Earnings Estimates

by Zacks Equity Research

ICU Medical (ICUI) delivered earnings and revenue surprises of 21.29% and 2.41%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Laboratories (BIO) Tops Q2 Earnings Estimates

by Zacks Equity Research

Bio-Rad (BIO) delivered earnings and revenue surprises of 17.65% and 0.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Abbott (ABT) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Abbott (ABT) delivered earnings and revenue surprises of 3.85% and 2.84%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Ensign Group (ENSG) Up 26% in a Year: More Room to Run?

by Zacks Equity Research

Ensign Group (ENSG) is well-poised for growth on the back of an aging U.S. population, an expanding healthcare portfolio and prudent deployment of capital.

UnitedHealth's (UNH) Program to Aid Georgia's Diabetic Patients

by Zacks Equity Research

UnitedHealth's (UNH) unit, UnitedHealthcare, extends its community-based program to improve the health conditions of Southwest Georgia's diabetic patients.

Tenet Healthcare (THC) Gains 42.1% YTD: More Room to Run?

by Zacks Equity Research

Tenet Healthcare's (THC) aim to boost USPI's network through continuous buyouts is positioning the company well for growth.

Here's Why You Should Hold UnitedHealth Group (UNH) Stock Now

by Zacks Equity Research

Membership growth, expanding government business and improving operating margin poise UnitedHealth Group (UNH) well for growth.

Here's Why You Should Retain Humana (HUM) in Your Portfolio

by Zacks Equity Research

Humana (HUM) remains well-poised for growth, attributable to a growing customer base, numerous contract wins and solid cash-generating abilities.

ICU Medical (ICUI) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

ICU Medical (ICUI) delivered earnings and revenue surprises of 26.09% and 2.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

TG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

TG Therapeutics (TGTX) delivered earnings and revenue surprises of 22.22% and 105.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ICU Medical (ICUI) Beats Q4 Earnings Estimates

by Zacks Equity Research

ICU Medical (ICUI) delivered earnings and revenue surprises of 6.67% and 0.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q4 Earnings Estimates

by Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 2.94% and 0.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ICU Medical (ICUI) Stock Jumps 5.8%: Will It Continue to Soar?

by Zacks Equity Research

ICU Medical (ICUI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

ICU Medical (ICUI) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

ICU Medical (ICUI) delivered earnings and revenue surprises of 24.11% and 6.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in PetIQ (PETQ): Can Its 9.3% Jump Turn into More Strength?

by Zacks Equity Research

PetIQ (PETQ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

New Strong Sell Stocks for September 8th

by Zacks Equity Research

CIEN, CYH and ICUI have been added to the Zacks Rank #5 (Strong Sell) List on September 8, 2022.

New Strong Sell Stocks for August 11th

by Zacks Equity Research

CBAN, ICUI, and NVDA have been added to the Zacks Rank #5 (Strong Sell) List on August 11, 2022.

ICU Medical (ICUI) Q2 Earnings and Revenues Lag Estimates

by Zacks Equity Research

ICU Medical (ICUI) delivered earnings and revenue surprises of -18.93% and 1.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ICU Medical (ICUI) Surpasses Q1 Earnings Estimates

by Zacks Equity Research

ICU Medical (ICUI) delivered earnings and revenue surprises of 1.68% and 0.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?